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Edited by Hans-Dieter KlenkAbstract Virus-like particles (VLPs) produced by recombinant
expression of the major viral structural proteins could be an
attractive method for severe acute respiratory syndrome (SARS)
control. In this study, using the baculovirus system, we generated
recombinant viruses that expressed S, E, M and N structural
proteins of SARS-CoV either individually or simultaneously.
The expression level, size and authenticity of each recombinant
SARS-CoV protein were determined. In addition, immunoﬂuo-
rescence and FACS analysis conﬁrmed the cell surface expres-
sion of the S protein. Co-infections of insect cells with two
recombinant viruses demonstrated that M and E could assemble
readily to form smooth surfaced VLPs. On the other hand,
simultaneous high level expression of S, E and M by a single
recombinant virus allowed the very eﬃcient assembly and release
of VLPs. These data demonstrate that the VLPs are morpho-
logical mimics of virion particles. The high level expression of
VLPs with correct S protein conformation by a single
recombinant baculovirus oﬀers a potential candidate vaccine
for SARS.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The severe acute respiratory syndrome (SARS)-associated
coronavirus (SARS-CoV), also named infectious atypical
pneumonia, is a newly emergent member in the family Coro-
naviridae [1]. SARS-CoV causes a transmissible febrile respi-
ratory disease for which an eﬀective and safe vaccine is
required [2]. SARS-CoV is phylogenetically distinct from other
characterized coronaviruses [3]. The genome is composed of a
relatively conserved region encoding an RNA-dependent RNA
polymerase and a variable region containing open reading
frames encoding sequences for viral structural proteins: spike
(S), envelope (E), membrane (M), and nucleocapsid (N) [4,5].
Like some other coronaviruses, the variable region of SARS-* Corresponding author. Fax: +44-0-207-7927-2839.
E-mail address: polly.roy@lshtm.ac.uk (P. Roy).
Abbreviations: SARS-CoV, severe acute respiratory syndrome-associ-
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californica; Sf9, Spodoptera frugiperda; WB, Western blotting; EM,
electron microscopy; PI, post-infection
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putative non-structural proteins whose function is largely un-
known [6].
In the Coronaviridae family, the envelope M protein is a
triple-spanning membrane glycoprotein that interacts with the
nucleocapsid and S protein during assembly [7]. Another
component essential in the assembly process is the small E
protein. This protein is generally a minor virion constituent. It
is largely embedded within the viral membrane and only its
hydrophilic carboxy terminus protrudes inside the virion [8,9].
The spike (S) protein, which is the second most abundant
envelope protein, is a large type-I transmembrane glycoprotein
that is responsible for receptor binding and membrane fusion
[10]. In coronaviruses infection, the S protein plays an im-
portant role in the immune responses against the virus as
neutralizing antibody, passive antibody protection, and cellu-
lar immunity have all been related to this protein [11]. How-
ever, multi-protein structures such as virus-like particles
(VLPs) composed of all major structural proteins that mimic
the organizations and conformations of authentic native par-
ticles but lack the viral genome would be more likely to
stimulate stronger cellular and humoral immune responses
compared to a single protein vaccine containing only the S
protein. Indeed, we have demonstrated for another animal
disease, bluetongue disease of sheep, that while single or
combined protein vaccines were protective in sheep against
virulent BTV infection, BTV-VLPs were much better vaccines
[12,13].
During coronavirus assembly, the N protein, which is lo-
cated inside the virion complexed with the viral RNA [14],
leads to the formation of the helical nucleocapsid. The M
protein is associated with specialized intracellular membrane
structures, and interactions between the M and E proteins and
nucleocapsids result in budding through the membrane [6].
The S protein is incorporated into the viral envelope, again by
interaction with M, and mature virions are released from the
plasma membrane [15].
Assembly of coronavirus capsid proteins by a heterologous
mammalian expression system has been reported for mouse
hepatitis virus [16–18] and the transmissible gastroenteritis
virus of swine [19]. However, assembly and expression of three
coronavirus membrane-associated proteins such as M, E and S
proteins of SARS at a high level by using the heterologous
insect cell protein expression system that was used to generate
BTV-VLPs could be a challenging task in comparison to
non-envelope BTV-VLPs.blished by Elsevier B.V. All rights reserved.
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expression vectors to express all four structural proteins of
SARS-CoV and to investigate the assembly of VLPs as a ﬁrst
step to the development of VLP vaccine for SARS. Our studies
here present clear evidence of the expression and spontaneous
assembly of the three structural proteins in appropriate mo-
lar ratios, as well as of their release from the cell surface as
VLPs.Fig. 1. Expression of S, N, M and E SARS proteins and detection of
VLPs in Sf9 infected cells. Sf9 cells were infected with single re-
combinant baculoviruses at a MOI of 4 and analyzed by (A) SDS–
PAGE followed by Coomassie blue staining and (B) WB analysis using
mouse anti-SARS polyclonal antibody. The ﬁgure shows the clearly
expressed SARS proteins when compared to the mock infected cells. It
should be noted that the M protein appears as a double band in the gel
and the larger form of the protein reacted poorly with our antibody.
(C) EM analysis of negatively stained cell sections revealed the pres-
ence of VLPs. These particles were visible in the cytoplasm after 2 days
co-infection with the M and E expressing recombinant baculoviruses.
Bar¼ 100 nm.2. Materials and methods
2.1. Cloning and construction of recombinant baculoviruses
The plasmid genes encoding the small envelope protein (E), the
membrane protein (M), the nucleocapsid protein (N) and the major
structural spike glycoprotein (S) of SARS cloned into a pCR-blunt-
TopoII vector (Invitrogen, Inc.), were obtained from Dr. Kirill Kalnin
(Acambis Inc., MA). The full-length M, N and E genes were ampliﬁed
by polymerase chain reaction (PCR) using primers which included
recognition sites for BamHI. The ampliﬁed genes were cloned into the
BamHI site of the pAcYM1 vector under the control of the polyhedrin
promoter. The full-length gene encoding the S protein was excised
from pBlunt vector with an EcoRI restriction enzyme digest, coupled
to BglII linkers and inserted into a BglII site of the baculovirus transfer
vector pTriEx-1. The correct orientation of the insertions was exam-
ined by PCR and restriction enzyme analysis. The constructs were co-
transfected with triple cut, linearized Autographa californica (AcNPV)
DNA to produce recombinant baculoviruses that individually ex-
pressed the M, N, E and S proteins.
In order to obtain a single recombinant baculovirus that expressed
the M, E and S proteins, two new constructs were generated. The ﬁrst
contained the S and E genes cloned into the BamHI and BglII sites,
respectively, of the pAcVC3 vector under the control of the polyhedrin
promoter. For the second construct, the M gene was inserted into the
BglII site under the control of the p10 promoter of a pAcP102x vector,
which also contains the GUS gene to allow easy selection of double
recombinants when transfected with AcNPV DNA in Spodoptera
frugiperda (Sf9) insect cells.
2.2. Puriﬁcation of VLPs
Assembled VLPs were isolated either from the cytoplasm of infected
cells or from the culture medium. Infected cells were pelleted by cen-
trifugation at 4000 rpm for 15 min, resuspended in TEN buﬀer (10 mM
Tris–HCl, pH 7.4, 1 mM EDTA, and 1 MNaCl) with 1% Triton X-100
and dounce-homogenized on ice. After centrifugation (3500 rpm for 30
min), the clariﬁed supernatant was centrifuged on a linear 30–45% (w/
w) sucrose gradient in TEN buﬀer at 27 000 rpm for 3 h. The opales-
cent band containing the particles was clearly visible in the middle of
the gradients. To isolate VLPs from the culture media of the infected
cells, the media were clariﬁed by centrifugation at 3500 rpm for 30 min
and then centrifuged at 27 000 rpm for 50 min on a 15% (w/w) sucrose
cushion in TEN buﬀer at 4 C. The pelleted particles were recovered in
TNE buﬀer (10 mM Tris–HCl, pH 7.4, 1 mM EDTA, and 0.1 M NaCl)
and stored for analysis. Alternatively, VLPs were further puriﬁed on a
linear sucrose gradient (30–45%, w/w) as above and recovered in TNE
buﬀer to a ﬁnal concentration of 1 lg/ll.
2.3. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE) and Western blotting
The Sf9 cells were harvested, lysed and resolved by 10% or 15%
SDS–PAGE [20]. The gels were either stained with Coomassie brilliant
blue or subjected to Western blotting (WB) analysis using appropriate
SARS-CoV antibodies [21].
2.4. Electron microscopy (EM)
For negative staining, aliquots of the VLP samples were placed on
plastic carbon-coated grids and stained with 2% phosphotungstic acid
(pH 5.2). Immunogold labeling was performed on VLP samples as
described previously [22]. For thin sectioning, infected cells were ﬁxed,
agar embedded and cut into smaller cubes. The cubes were embedded
in epoxy resin and ultrathin sections were cut and mounted onto
copper grids. All the samples were examined on a Jeol 1200EX
transmission microscope.2.5. Immunoﬂuorescence and ﬂuorescence-activated cell sorter (FACS)
analysis
The Sf9 cells were grown in chamber slides and infected with the
recombinant baculovirus at an MOI of 4 for 48 h, immunoﬂuorescence
analysis was performed as described previously [23] and examined on a
Zeiss LSH 510 microscope. For FACS analysis, Sf9 cells were infected
as mentioned above and the analysis was performed as described
previously [23], on a Becton–Dickinson FACSCalibur analyser run-
ning CellQuest software (Becton–Dickinson).3. Results
3.1. Generation of recombinant baculoviruses expressing
individual SARS-CoV proteins: inter-protein interactions
in the formation of capsid structures
To determine whether each of the major SARS-CoV pro-
teins could be expressed by single recombinant baculoviruses,
each structural gene was used to generate a recombinant
baculovirus that expressed the S, E, M or N proteins indi-
vidually in Sf9 cells. Selected recombinant viruses were am-
pliﬁed and the expression of SARS-CoV protein was analyzed
by SDS–PAGE in Sf9 infected cells. Each recombinant virus
synthesized a protein of the expected size of the SARS-CoV
proteins S, N, M or E (Fig. 1A). In addition, the speciﬁcity and
authenticity of each recombinant protein were conﬁrmed by
WB analysis with mouse anti-SARS polyclonal antibody
(Fig. 1B).
To determine if these recombinant proteins could interact
with each other and assemble into particulate structures, Sf9
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M, E or S alone or co-infected in combination of M and E; M
and S or M, E and S. EM analysis of the negatively stained
infected cell sections exhibited no particulate structures when
each protein was expressed alone. However, cells infected with
recombinant viruses expressing M and E had large numbers of
particulate structures, with a diameter of approximately 100
nm, distributed throughout the cytoplasm (Fig. 1C). In con-
trast, no structures could be detected in the cells that were co-
infected with recombinant viruses expressing M and S. The
results demonstrate that the M and E proteins were suﬃcient
for the assembly of particles but in the absence of the E pro-
tein, M and S could not assemble into VLPs. Cells co-infected
with three diﬀerent recombinant baculoviruses (M, E and S)
resulted insuﬃcient quantity of particles, assembled with three
proteins, to be detectable by our assay system (data not
shown).
To obtain puriﬁed VLPs containing M and E proteins, Sf9
cells were co-infected with two recombinant baculoviruses
expressing M and E proteins, 48 h post-infection (PI) cells were
lysed and VLPs were puriﬁed by sucrose gradient centrifuga-
tion. The assembled particles were isolated and the expression
of SARS-CoV proteins was assessed by SDS–PAGE. Only two
protein bands were visible, one of approximately 30 kDa in
size, corresponding to the M protein and the other of 10 kDa
in size identical to the E protein size. M protein runs slightly
slower than the predicted size of 25 kDa in this analysis,
probably due to the glycosylation of the protein on expression
in the baculovirus system. The sucrose gradient puriﬁcation
revealed that the two SARS envelope proteins, M and E, could
indeed self-assemble into particles (Fig. 2A). Importantly, WB
analysis conﬁrmed that the two visible bands were M and E
proteins, which reacted with the mouse anti-SARS polyclonal
antibody (Fig. 2B). To visualize the VLP morphology, the
VLPs were examined by negative staining and EM. Smooth
particles with approximate diameter of 100 nm were visualized,
indicating that the VLPs were stable enough to tolerate theFig. 2. Analysis of VLPs formed by Sf9 cells co-infected with M and
E expressing recombinant baculoviruses. The VLPs were puriﬁed
using a sucrose gradient and the protein composition was determined
by (A) SDS–PAGE followed by Coomassie blue staining and (B) WB
analysis using a mouse anti-SARS polyclonal antibody. (C) EM of
negatively stained smooth SARS VLPs puriﬁed by sucrose gradient.
Bar¼ 100 nm.puriﬁcation regime and the EM staining reagents (Fig. 2C). In
the absence of S protein expression, there were no spike pro-
jections and this gave an even, smooth appearance to the
spherical particles.
3.2. Generation of a recombinant baculovirus expressing three
SARS proteins and demonstration of SARS-VLPs
assembly and release
In order to enhance the VLP assembly, a triple recombinant
baculovirus that would express S, M and E proteins was
generated. When protein expression by this recombinant virus
was assessed by SDS–PAGE, very high levels of expression of
SARS proteins, particularly S and M proteins, were achieved
approaching 500 lg recombinant protein per 1 106 infected
cells (Fig. 3A). WB analysis of the infected cell lysate using a
mouse anti-SARS polyclonal antibody revealed the presence of
all three SARS-CoV proteins (Fig. 3B).
By immunoﬂuorescence, we examined the SARS-CoV S
protein for expression on the surface of the Sf9 cells when
infected with the triple recombinant baculovirus. The S gly-
coprotein was observed at the periphery of the ﬁxed infected
cells, demonstrating the distribution of the S protein on the
plasma membrane (Fig. 3C). Also, FACS analysis, using anti-S
monoclonal antibody, clearly demonstrated the expression of
the S protein on the live cell surface in comparison to the
uninfected control cells (data not shown).
To discern if assembled VLPs, containing the S envelope
glycoprotein, were indeed released from the infected cell,
mimicking the coronavirus morphogenesis, Sf9 cells were in-
fected with the triple recombinant baculovirus and were har-
vested at a time course of 48, 72 and 96 h PI. Both the cell
lysates and culture medium were examined for the presence of
VLPs. All three proteins were visible in both cell lysates and inFig. 3. Expression of S, M and E SARS proteins in Sf9 infected cells.
To examine protein expression levels, the cells were infected with the
triple recombinant baculovirus at a MOI of 4 and analyzed by (A)
SDS–PAGE followed by Coomassie blue staining and (B) WB analysis
using mouse anti-SARS polyclonal antibody. (C) Immunoﬂuorescence
analysis of ﬁxed cells infected with the triple recombinant baculovi-
ruses. Expression of the SARS S glycoprotein was detected with a
primary anti-S monoclonal antibody and secondary anti-mouse FITC-
conjugated antibody, on the plasma membrane of infected cells.
Bar¼ 10 lm.
Fig. 5. Analysis of VLPs released from Sf9 cells infected with the triple
recombinant baculovirus. Sucrose gradient puriﬁed VLPs from the
supernatant of infected cells were analyzed by (A) SDS–PAGE fol-
lowed by Coomassie blue staining and (B) WB analysis using a mouse
anti-SARS polyclonal antibody. This ﬁgure shows the protein bands of
the S, M and E SARS proteins. (C) EM of the negatively stained spiky
SARS-VLPs puriﬁed by sucrose gradient from the culture medium of
infected cells. Bar¼ 100 nm. (D) Electron micrograph of immunogold-
labeled SARS-VLPs. The VLPs were probed using an anti-S
monoclonal antibody counterstained with gold spheres coupled to
anti-mouse IgG.
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protein was present in the cells both at 48 and 72 h, but not in
the medium. However, at 96 h larger amounts of proteins were
synthesized and released into the medium (Fig. 4). Therefore,
assembled VLPs released at 96 h PI were subjected to further
investigation.
The SDS–PAGE analysis of putative VLPs puriﬁed from the
supernatant showed three distinct protein bands of approxi-
mately 180, 30 and 10 kDa corresponding to the S, M and E
SARS-CoV proteins, respectively (Fig. 5A). The expression of
authentic proteins was subsequently conﬁrmed by WB analy-
sis, using a mouse anti-S polyclonal antibody (Fig. 5B).
In order to investigate whether the N protein could be in-
corporated within the VLPs, Sf9 cells were co-infected with the
triple recombinant baculovirus together with the single re-
combinant virus expressing the N protein. Despite the fact that
the N protein was expressed in the infected Sf9 cells, the ex-
amination of the puriﬁed VLPs released into the media 96 h PI
still had only S, M and E proteins but did not exhibit the
presence of the N protein (data not shown).
3.3. Morphology of released VLPs and the presence of S protein
on the particles
We used EM analysis, to examine if the morphology of
VLPs that consist of S protein in addition to the M and E
proteins is diﬀerent to the VLPs formed by only the M and E
proteins. The negatively stained VLPs exhibited a very diﬀer-
ent morphology to that of the M and E. VLPs with the S
protein had a spherical morphology with distinctive ﬁne spike
projections (Fig. 5C). Clearly, the three SARS-CoV proteins
synthesized by a triple recombinant baculovirus in insect cells
had interacted with each other and assembled into VLPs that
were subsequently released from these cells. Thus, the VLPs
not only closely resembled SARS-CoV virus in size and par-
ticle morphology but also the virus morphogenesis. The yield
of VLP from infected cells was approximately 200 lg VLP per
1 109 infected cells.
The display of spikes ornamenting the surface of the VLPs
was clearly visible as distinct projections and the presence of
the S protein was conﬁrmed by immunogold labeling
(Fig. 5D). We were not able to identify the M protein by im-
munogold labeling and EM, perhaps due to low abundance of
the M protein on the VLPs surface or inaccessibility of the M
epitopes. However, the presence of the M protein was estab-Fig. 4. Time course of SARS-VLPs release from Sf9 infected cells. Sf9
cells were infected with the triple recombinant baculovirus at a MOI of
4 and at the indicated times cell lysates (lanes 1–3) and cell culture
medium (lanes 5–7) were analyzed by SDS–PAGE followed by Coo-
massie blue staining. This ﬁgure shows the location of the VLPs for
puriﬁcation procedures. Lane 4, Sf9 mock infected control.lished by the fact that the M protein is absolutely necessary in
the organization of the viral envelope during assembly [7].4. Discussion
In this paper we describe the production of SARS-CoV-like
particles, by expression of the viral structural proteins in the
baculovirus system. By co-expression of the M and E proteins
we were able to produce well assembled, spikeless but stable
VLPs. These smooth surfaced particles are probably an in-
termediate particle in virus assembly. The formation of VLPs
by these two proteins has been reported for other coronavi-
ruses [16–19], and a very recent report has been published
regarding the production of SARS-VLPs by multiple co-in-
fection with single baculoviruses expressing M, E and S pro-
teins individually. In this report, the VLPs did not bud from
the insect infected cells but instead they were isolated from cell
lysates [24]. However, when we co-infected Sf9 cells with three
recombinant viruses expressing M, E and S proteins, we were
not able to generate stable VLPs with the spike protein on the
surface that could be isolated from culture medium. For this
reason and because of the ineﬃciency of the assembly process
by co-infection with several recombinant baculoviruses, we
generated a single recombinant baculovirus that expressed all
three SARS proteins simultaneously. This, in turn, means that
every infected cell in a culture receives all of the structural
proteins of the virus and expresses them all at the same time.
This feature is particularly important for the eﬃcient assembly
of multi-protein complexes where simultaneous infection with
multiple baculoviruses is essential.
This is the ﬁrst report describing the co-expression of the
three SARS proteins (M, E and S) at very high level from a
178 E. Mortola, P. Roy / FEBS Letters 576 (2004) 174–178single recombinant baculovirus that allows spontaneous as-
sembly of highly stable VLPs. Glycosylated S protein formed
very distinct spikes on the surface of the VLPs as can be ob-
served in Fig. 5C. VLPs budded from the plasma membrane of
infected cells, similar to the authentic virions, allowing puriﬁ-
cation from the culture medium.
Previous studies on coronaviruses have indicated that the
production of VLPs is dependent on the expression of the
M and E proteins, but that the infectivity of VLPs is de-
pendent on S protein [25]. The spike protein is the receptor
binding protein, it has a crucial role during infection of
cells and it is the main target for a protective humoral
immune response [26]. In our study, the expression of the S
protein was very high and the incorporation of S glyco-
protein onto the surface of the VLPs makes these particles
not only a powerful instrument for studies of the assembly
and budding of SARS-CoV particles but also as a candidate
vaccine and a tool for SARS diagnosis. Self-assembly of
viral capsid proteins into VLPs for both RNA and DNA
viruses has been reported and VLPs produced by this sys-
tem usually retain the immunogenic and physiochemical
properties of the native virions [27–32].
In our analysis, the E protein was only expressed in small
amounts, although this protein was essential for the formation
of VLPs. Thus, we can hypothesize that as with other coro-
naviruses [18,33,34], the protein component of these particles
essentially consists of a matrix of laterally interacting M pro-
teins, which in some way require the E protein for budding
and, if available, the S protein is incorporated by speciﬁc in-
teractions with M. We showed that the VLPs that were formed
consisted of only the M, E and S proteins but not the N
protein, indicating that N protein was not able to be incor-
porated. However, it was not unexpected that the SARS-CoV
like particles were formed without the inclusion of nucleo-
capsid protein, as other coronaviruses also form VLPs in the
absence of the N protein [16].
The approach presented here will allow us to further study
the virus neutralization properties of SARS-CoV VLPs, as well
as viral morphogenesis. Our data suggest that the VLPs hold
promise for creating novel recombinant vaccine against SARS
and possibly for other pathogens, in addition to understanding
the protein–protein interactions in virus assembly.
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